Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Kaplan-Meier estimates of median progression-free survival (PFS, dotted line) and overall survival (OS, straight line) for all patients (N = 46).
Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases | Article
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma | NEJM
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
Kaplan–Meier survival curves. (A) Median overall survival was... | Download Scientific Diagram
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
Survival (time to event) data: median survival times | The BMJ
View Image
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Survival Analysis in R
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Cureus | Impact of CyberKnife Radiosurgery on Median Overall Survival of Various Parameters in Patients with 1-12 Brain Metastases | Media
